Al­ler­gan chief snaps up a ri­val biotech for $195M in cash, plus. Deal beefs up the aes­thet­ics pipeline

Just af­ter the start of the year, the crew of ex-Al­ler­gan ex­ecs that launched Bon­ti raised more than $15 mil­lion to back their de­vel­op­ment of a ri­val bot­u­linum neu­ro­tox­in dubbed EB-001 for ther­a­peu­tic and aes­thet­ic us­es.

And Al­ler­gan $AGN wants it.

The bio­phar­ma com­pa­ny has wrapped a deal to buy Bon­ti for $195 mil­lion up­front, mark­ing a nice pay­back for the founders and in­vestors, who had gath­ered a bit more than $36 mil­lion for the ven­ture. There are mile­stones, but no one spelled it out in the re­lease out Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER